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As pressure increasingly builds on
public and charitable sources of
research funding, there is growing
concern that money from the
pharmaceutical industry may
come with pitfalls for unwary
researchers, Britain’s science
academy, the Royal Society,
concluded last month.
Royal Society members, who
held their annual alumni meeting,
fear that the government’s drive to
increase university-industry
collaboration on research could
lead to scientific results becoming
biased. Patrick Bateson, the
society’s vice-president, said that
commercial opportunities were
already affecting the choice of
research topics. He said that
scientists were leaning towards
projects with short-term financial
benefits instead of concentrating
on long-term public need.
He said: “We want to counter
the trend towards more and more
funding from industry. We want to
push in the other direction from
government.” He said that many
scientists were not aware of the
potential pitfalls of corporate
funding and that the effects of
commercial influence on research
could be subtle.
Bateson said that universities
urgently needed to consider how
to maintain model standards of
scientific conduct and he called
for a clear code of conduct in
universities and tougher
negotiations on commercial
contracts. “I’m sure this advice is
not generally available. This is
something people have hardly
started to think about.”
Bateson was worried about the
unconscious bias that may be
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There is growing concern that increasing dependence on industrial
funding may bias the direction of academic research programmes and
Britain’s Royal Society believes action is needed to protect basic
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Drug pushing: The pharmaceutical industry is taking an ever greater role in funding academic research but the Royal Society in
Britain is concerned that controls are in place to protect academic freedom. (Picture: Science Photo Library.) 
present in the planning of
experiments. “We need to develop
ways of better training
researchers in methodology to
avoid this,” he said.
Sir David Weatherall, founding
director of the Weatherall Institute
of Molecular Medicine at Oxford
University, said: “For medicine it’s
a way of life to be supported by the
pharmaceutical industry. If you’ve
been looked after by these people,
unconscious bias is dangerous.”
He said that universities had to
wake up to the issues and ensure
they had had proper systems in
place to monitor funding streams
coming into departments from
industry and government. “There
are problems – perhaps it’s
inevitable as things have moved so
fast in the past five years and it’s
now time to stand back and deal
with them.”
In spite of increasing
government funds for research
over recent years, industry
funding is also increasing. It was
reported last month that the
Wellcome Trust Biocentre at
Dundee University had won one of
the biggest ever industrial
research deals worth £15 million
over the next five years from
Pfizer, GlaxoSmithKline, Zeneca,
Boehringer Ingelheim and Merck
to support research on protein
phosphorylation. Such projects
come at a time of increasing
problems for non-industrial
funding agencies.
The meeting considered a
register of interests might help but
Sir David King, the government’s
chief scientific adviser, said that
this might be too intrusive. “If
there’s a scientist just carrying out
his or her normal business and
occasionally they receive grants
from different companies, I don’t
think that in any way means they
are beholden to those companies
or biased.”
He supported concerns raised
by Professor Bateson but valued
the  energizing effect of
commercial partnerships. “What
we mustn’t lose sight of is the
tremendous excitement that
arises from working at the
coalface of research but at the
same time finding there are real-
world applications for what you
are doing,” he said.
Four months into the new year,
German funding agencies
including the Deutsche
Forschungsgemeinschaft (DFG)
and the Max-Planck society
(MPG) are still unable to finalize
their budget for 2003. Last
November, the federal
government announced a budget
freeze (Current Biology 13, R43),
but this decision, which is in
contradiction to pre-election
promises of a 3% increase, has so
far failed to find the approval of
the committee of federal and
Länder governments (Bund-
Länder-Kommission, BLK), which
convened twice without coming to
an agreement.
Sources suggest that the DFG
has managed to carve out a
special solution for itself, with a
possible budget rise of up to
2.5%. At the Max-Planck society,
however, the preliminary budget is
set on the assumption that the
budget freeze will be
implemented. The inevitable
response of the society will be to
proceed with a consolidation
programme which was outlined by
MPG president professor Peter
Gruss last December in response
to the first announcement of a
freeze.
Pointing to the fact that the
budget conditions had already
been tight for many years, Gruss
announced the closure of 20
departments (Abteilungen),
representing just under 10% of
the society’s research facilities.
Most of the closures will take
advantage of the retirement of
existing directors. The general
policy of the society has always
been that departments, each of
which is dedicated to one topical
research field, may be shut down
on retirement of the director, to
make place for a new department
focussed on a new field. So the
main difference now is that —
over the next seven years or so —
20 departments will be closed
without replacement, which will
reduce the size of institutes and
possibly lead to the closing down
of a few smaller ones. It is
expected that the Senate, the
steering committee of the society,
will approve the consolidation
plan and this year’s budget at its
meeting on June 5th. After this
meeting, the president will decide
on the closures after consultation
with the institutes concerned. So
far, no specific closures can be
officially confirmed.
While there had been fears that
the need for consolidation might
put the ‘reconstruction plan’ for
the former East Germany at risk,
the society’s press secretary, Dr
Bernd Wirsing, insists that “this
plan will go ahead, although some
of the new institutes may end up
having fewer departments than
we originally planned.” Overall,
most of the programme for East
Germany has already been
implemented, and the 20 institutes
that sprang from it are up and
running, teeming with 4,000
employees. Thus, the East/West
division is no longer a central
issue and the new consolidation
program will not include any
geographical discrimination in
either direction.
Even after a 10% cutback, the
Max-Planck society will
undisputedly remain the major
player for fundamental research
in Germany. The challenge for the
society is, however, to remain
competitive internationally. It is
Germany’s most efficient dam
against the brain drain, and any
cost-cutting that undermines this
function might in the end cost
more than it saves.
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Germany, the largest country in the European Union, has been
suffering deep and long-term economic problems since reunification
more than a decade ago. Budget cutbacks now threaten some of its
most prestigious research institutions which may have to close some
of their departments to cope with threatened cuts. Michael Gross
reports. 
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